Head-to-head comparison of PT-141 (Bremelanotide) and Kisspeptin-10 for sexual health optimization. Compare mechanisms, onset, dosing, and who each peptide is best suited for.
Melanocortin receptor agonist (MC3R and MC4R) that activates central dopaminergic pathways involved in sexual arousal — acting directly on the hypothalamus to generate desire independent of vascular mechanisms.
Neuropeptide that activates the GPR54 (KISS1R) receptor on GnRH neurons in the hypothalamus, stimulating the hypothalamic-pituitary-gonadal (HPG) axis to increase LH, FSH, and downstream testosterone and estradiol production.
Side-by-Side Comparison
| Property | PT-141 | Kisspeptin-10 |
|---|---|---|
| Category | Melanocortin | Melanocortin |
| Mechanism | Melanocortin receptor agonist (MC3R and MC4R) that activates central dopaminergic pathways involved in sexual arousal — acting directly on the hypothalamus to generate desire independent of vascular mechanisms. | Neuropeptide that activates the GPR54 (KISS1R) receptor on GnRH neurons in the hypothalamus, stimulating the hypothalamic-pituitary-gonadal (HPG) axis to increase LH, FSH, and downstream testosterone and estradiol production. |
| Half-Life | ~2.7 hours | ~30 minutes |
| Typical Dosage | 1–2 mg SC or intranasal, 1–2 hours before activity | 1–10 mcg/kg SC, protocol varies |
| Primary Use | Sexual arousal and desire, erectile function, HSDD treatment (FDA approved for women) | HPG axis stimulation, testosterone optimization, reproductive hormone support, fertility |
| Onset | 30–60 minutes; peak effect at 1–2 hours | LH/testosterone elevation measurable within 1–2 hours; hormonal axis effects build over weeks |
| Stacks Well With | Kisspeptin-10, MT-2 | PT-141, Sermorelin, CJC-1295 |
Overview
Melanocortin receptor agonist (MC3R and MC4R) that activates central dopaminergic pathways involved in sexual arousal — acting directly on the hypothalamus to generate desire independent of vascular mechanisms.
Neuropeptide that activates the GPR54 (KISS1R) receptor on GnRH neurons in the hypothalamus, stimulating the hypothalamic-pituitary-gonadal (HPG) axis to increase LH, FSH, and downstream testosterone and estradiol production.
Applications & Benefits
- FDA-approved for hypoactive sexual desire disorder (HSDD) in women as Vyleesi
- Central mechanism works regardless of vascular health
- Fast onset — 30–60 minutes to effect
- Effective in both men and women across clinical studies
- Does not require continuous use — on-demand dosing
- Addresses root hormone axis rather than direct arousal pathways
- Increases endogenous testosterone and LH in research models
- Potential fertility support applications (HPG axis optimization)
- Clean safety profile in human clinical studies
- Works at the hormonal foundation level, not just symptomatic relief
PT-141 vs Kisspeptin-10: Bottom Line
PT-141 and Kisspeptin-10 operate through completely different pathways, making them tools for different problems rather than direct competitors. PT-141 is the acute arousal compound — fast onset, central dopaminergic mechanism, FDA-validated for women's HSDD. It works regardless of testosterone levels and is best for on-demand use. Kisspeptin-10 is a hormonal axis compound — it stimulates the GPG axis to drive LH and testosterone elevation, addressing the upstream hormonal foundation of sexual function. For acute arousal and performance, PT-141 is the first choice. For hormonal optimization and fertility-adjacent protocols, Kisspeptin-10 is the appropriate tool. Advanced protocols use both: PT-141 for direct performance support while Kisspeptin-10 works at the hormonal foundation level.
Compare Other Peptides
Mix and match any of the 19 peptides in our catalog for a custom side-by-side comparison.
Build New Comparison